164 related articles for article (PubMed ID: 26603185)
1. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines.
Jabbour E; Makenbaeva D; Lingohr-Smith M; Lin J
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):797-802. PubMed ID: 26603185
[TBL] [Abstract][Full Text] [Related]
2. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
3. Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.
Batar P; Alizadeh H; Rokszin G; Abonyi-Toth Z; Demeter J
Pathol Oncol Res; 2024; 30():1611497. PubMed ID: 38444749
[No Abstract] [Full Text] [Related]
4. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
6. Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States.
Coutinho AD; Makenbaeva D; Farrelly E; Landsman-Blumberg PB; Lenihan D
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):676-683. PubMed ID: 28729178
[TBL] [Abstract][Full Text] [Related]
7. Integrating current treatment options for TKI-resistant chronic myeloid leukemia.
Radich JP; Shah NP; Mauro MJ
Clin Adv Hematol Oncol; 2014 Jul; 12(7 Suppl 13):3-17, 1. PubMed ID: 25768408
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
9. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
10. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
[TBL] [Abstract][Full Text] [Related]
11. Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.
Franklin M; Burns L; Perez S; Yerragolam D; Makenbaeva D
Curr Med Res Opin; 2018 Feb; 34(2):353-360. PubMed ID: 29095654
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.
Machado-Alba JE; Machado-Duque ME
Int J Clin Pharm; 2017 Aug; 39(4):851-859. PubMed ID: 28508322
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
16. Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis.
Saußele S; Kohlbrenner K; Vogelmann T; Schubert T
Oncol Res Treat; 2022; 45(7-8):400-407. PubMed ID: 35340007
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
19. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
Kenzik KM; Bhatia R; Williams GR; Bhatia S
Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
